Literature DB >> 9713013

Genetic testing for maturity onset diabetes of the young in childhood hyperglycaemia.

K A Matyka1, F Beards, M Appleton, S Ellard, A Hattersley, D B Dunger.   

Abstract

Mild hyperglycaemia is a common finding during minor illness in children. The differential diagnosis includes maturity onset diabetes of the young (MODY), which can be a difficult diagnosis to make clinically. As most genes resulting in MODY have been identified, it is possible to make a firm diagnosis using mutation detection. A case is reported of a 4 year old girl in whom a diagnosis of MODY2 was established by the finding of a heterozygous missense mutation in exon 7 of the glucokinase gene, resulting in the substitution at codon 259 of alanine by threonine (A259T). Observations from other glucokinase families suggest that hyperglycaemia in this child is likely to be stable and will not require intensive medical follow up, whereas other forms of MODY (1, 3, and 4) might carry a different prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713013      PMCID: PMC1717591          DOI: 10.1136/adc.78.6.552

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  8 in total

1.  Early-onset type-II diabetes mellitus (MODY4) linked to IPF1.

Authors:  D A Stoffers; J Ferrer; W L Clarke; J F Habener
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

2.  Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families.

Authors:  G Velho; H Blanché; M Vaxillaire; C Bellanné-Chantelot; V C Pardini; J Timsit; P Passa; I Deschamps; J J Robert; I T Weber; D Marotta; S J Pilkis; G M Lipkind; G I Bell; P Froguel
Journal:  Diabetologia       Date:  1997-02       Impact factor: 10.122

3.  Mild familial diabetes with dominant inheritance.

Authors:  R B Tattersall
Journal:  Q J Med       Date:  1974-04

4.  Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3)

Authors:  K Yamagata; N Oda; P J Kaisaki; S Menzel; H Furuta; M Vaxillaire; L Southam; R D Cox; G M Lathrop; V V Boriraj; X Chen; N J Cox; Y Oda; H Yano; M M Le Beau; S Yamada; H Nishigori; J Takeda; S S Fajans; A T Hattersley; N Iwasaki; T Hansen; O Pedersen; K S Polonsky; G I Bell
Journal:  Nature       Date:  1996-12-05       Impact factor: 49.962

5.  Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1)

Authors:  K Yamagata; H Furuta; N Oda; P J Kaisaki; S Menzel; N J Cox; S S Fajans; S Signorini; M Stoffel; G I Bell
Journal:  Nature       Date:  1996-12-05       Impact factor: 49.962

6.  Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K.

Authors:  T M Frayling; M P Bulamn; S Ellard; M Appleton; M J Dronsfield; A D Mackie; J D Baird; P J Kaisaki; K Yamagata; G I Bell; S C Bain; A T Hattersley
Journal:  Diabetes       Date:  1997-04       Impact factor: 9.461

7.  Distinction between transient hyperglycemia and early insulin-dependent diabetes mellitus in childhood: a prospective study of incidence and prognostic factors.

Authors:  R Herskowitz-Dumont; J I Wolfsdorf; R A Jackson; G S Eisenbarth
Journal:  J Pediatr       Date:  1993-09       Impact factor: 4.406

8.  Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus.

Authors:  P Froguel; H Zouali; N Vionnet; G Velho; M Vaxillaire; F Sun; S Lesage; M Stoffel; J Takeda; P Passa
Journal:  N Engl J Med       Date:  1993-03-11       Impact factor: 91.245

  8 in total
  1 in total

1.  Glucokinase (GCK) mutations and their characterization in MODY2 children of southern Italy.

Authors:  Marina Capuano; Carmen Maria Garcia-Herrero; Nadia Tinto; Carla Carluccio; Valentina Capobianco; Iolanda Coto; Arturo Cola; Dario Iafusco; Adriana Franzese; Adriana Zagari; Maria Angeles Navas; Lucia Sacchetti
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.